Olumiant (baricitinib and external corticosteroids in Phase 3 clinical trial scored the main endpoint)

Asexual dermatitis is a serious chronic, recurrent skin diseaseThe main symptoms are itching, dry skin and inflammation, which can occur in any part of the bodyRecently, Lilly(http://and Incyte jointly announced that THE JAK inhibitor Olumiant (baricitinib) in combination with the external corticosteroids, in the treatment of patients with severe asexual dermatitis in the stage 3 clinicaltrial(http://the main endpointAbout Baricitinib
Baricitinib is a daily oral JAK inhibitor, and Baricitinib has been approved by the U.SFDA(http://to treat patients with moderate to severe active rheumatoid arthritis who are under-reacted to TNF inhibitor therapyIn the study
patients with moderate and severe atopic dermatitis received baricitinib in addition to standard epicortical steroid sparing steroids in a key Phase 3 clinical trial called BREEZE-AD7 　　The results showed that the combination of baricitinib with standard therapies significantly improved the severity of the disease 　　Using a vIGA score of asexual dermatitis, the percentage of patients who reached the main end of the trial at the 16th week of treatment, with the proportion of patients who achieved skin symptom removal or almost elimination (vIGA-0,1) was significantly higher than in the placebo group